Abstract
Non-small cell lung cancer (NSCLC) is a kind of refractory lung cancer. Under traditional cisplatin treatment, it is difficult for patients, especially the advanced cancer patients, to have a high cure rate and survival rate. Abnormal histological variants may lead to NSCLC. Mutations in C-MET may lead to abnormal downstream metabolism, which in turn triggers unrestricted cell growth and metastasis. Therefore, C-MET inhibitors can inhibitive the overexpression and activation of C-MET by blocking the gene pathway, in result in that the growth and the spread of cancer cell can be inhibitived. A variety of C-MET inhibitors such as crizotinib, cabonitinib, capmatinib, etc., have been found to have good therapeutic activity and considerable clinical data. This paper discussed the C-MET as a therapeutic target in NSCLC, and outline the applications in clinical and therapeutic effects of various C-MET inhibitors.
Publisher
Darcy & Roy Press Co. Ltd.
Reference24 articles.
1. Peixin Chen, Caicun Zhou. Progress and prospect of drug therapy for non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 37(1): 33-39.
2. Rebuzzi SE, Zullo L, Rossi G, et al. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. Int J Mol Sci. 2021 Mar 5; 22(5): 2625.
3. D Zheng, R Wang, T Ye, et al. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer. Oncotarget, 7 (2016), pp. 41691-41702,
4. Giulia Pasquini, Giuseppe Giaccone. C-MET inhibitors for advanced non-small cell lung cancer, Expert Opinion on Investigational Drugs, 2018.
5. K. Matsumoto, M. Umitsu, D.M. De Silva, et al.Hepatocyte growth factor/MET in cancer progression and biomarker discovery. Cancer Sci, 108 (2017), pp. 296-307.